Publicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (11)

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

2021

  1. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 9, pp. 1517-1525

2020

  1. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2018

  1. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

    PLoS ONE, Vol. 13, Núm. 4

  2. Real world patient-reported outcomes in HIV-infected adults switching to EVIPLERA®, because of a previous intolerance to cART. PRO-STR study

    Current HIV Research, Vol. 16, Núm. 6, pp. 425-435

2017

  1. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

2015

  1. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial

    BMJ Open, Vol. 5, Núm. 3

2012

  1. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

    Farmacia Hospitalaria, Vol. 36, Núm. 1

  2. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 1

2011

  1. Programs to optimize antimicrobial use (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document

    Medicina Preventiva, Vol. 17, Núm. 3, pp. 29-39

2009

  1. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201